The therapeutic potential of M1R inhibition extends beyond diabetic neuropathy to other peripheral neuropathies such as those caused by chemotherapies (termed chemotherapy-induced peripheral neuropathy: CIPN) and human immunodeficiency virus (HIV) [132]. Here, CHRM1 is linked to peripheral neuropathy.